The significant costs, extended timelines, and regulatory hurdles facing emerging life science companies in today's economy make it increasingly difficult for VCs to make a sizable return on their investment. Can the same be said for corporate investors, or do they have different objectives? What is driving their investment strategy? Is it strategic alignment, an attempt at harnessing innovation, or simply good business? Join us at our next industry panel for an interactive discussion on why and how corporate players are getting in the game and hitting it big! Could this be the changing of the guard in life sciences? Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
CONFIRMED & INVITED PANELISTS
Tiba Aynechi, Principal in Novo Ventures, Novo A/S
Martin Eglitis, Senior Partnering Director, Teva Pharmaceuticals
Juan Harrison, Vice President, Takeda Research Investment
Brian Piper, Senior Director, Strategic Investment Group, Shire Pharmaceuticals
DISCLAIMER: Our aim is to continuously provide our
progressive audience with an open and interactive medium to view
and share relevant,
beneficial and interesting "career, economic, lifestyle and
networking" listings, ads, content and resources.
While the above information may be accurate and viable, the role
of Minority Professional Network, Inc. (MPN) is
strictly as a communications medium, and we do not
accept any responsibility for
cancellation, changes, errors, omissions, inconveniences, or any other form
of liability for any content
displayed or disseminated via our web sites, or e-marketing or social media
promotional services.
If there are any
doubts, we
encourage you to conduct additional research or contact the listed host or responsible entity.
CLICK HERE to inform us about any ads, listings or content
which appear to be
inappropriate,
fraudulent or misleading, or inconsistent with our theme and focus.